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Results: Locoregional recurrence was significantly lower in 
the short time-interval group (Fig. 1). Recurrence rate at 2 
years was 11% (95%CI 3-36%) in the short time-interval group 
compared to 49% (95%CI 30-73%) in the long time-interval 
group. The stepwise Cox regression identified time-interval 
(a short interval is better), T90 (higher temperatures are 
beneficial) and age (younger age is unfavourable) as 
significant prognostic factors, and shows a favourable trend 
for lower FIGO stage (Table 1). 
Overall survival was also significantly better in the short 
time-interval group (Fig. 1). Overall survival at 2 years was 
60% (95%CI 39-75%) in the short group compared to 39% 
(95%CI 21-56%) in the long time-interval group. The stepwise 
Cox regression identifies a short time-interval and higher T90 
as significant factors for a favourable outcome (Table 1). 
 
 
 
Fig. 1. Kaplan-Meier curves for locoregional recurrence (left) 
and overall survival (right) after EBRT and HT for advanced 
cervical cancer, grouped by time-interval between EBRT and 
HT. 
Table 1 Results of the Cox multivariable analysis of 
locoregional recurrence and survival after radiotherapy and 
hyperthermia for advanced cervical cancer. 
 
 
 
Conclusion: A short time interval between EBRT and HT 
results in a significantly lower recurrence and better overall 
survival for locally advanced cervical cancer patients. 
Furthermore, a higher tumour temperature during HT is 
associated with lower locoregional recurrence and better 
overall survival, stressing the importance of HT quality 
assurance. 
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Purpose or Objective: To define the recommended dose in 
high-intermediate risk endometrial cancer (HIR-EC) patients 
postoperatively irradiated by simultaneous integrated boost 
volumetric modulated arc therapy (SIB-VMAT). 
 
Material and Methods: A radiation dose of 45 Gy over 5 
weeks, 1.8 Gy/fraction, was delivered to the vagina and the 
lymphatic drainage (planning target volume, PTV2). Radiation 
dose was escalated to the upper two thirds of vagina (PTV1) 
with the SIB-VMAT strategy, after 1 year follow up of the first 
15 patients. Two dose levels were planned: Level 1 (PTV2: 
45/1.8 Gy; PTV1: 55/2.2 Gy), and Level 2 (PTV2: 45/1.8 Gy; 
PTV1: 60/2.4 Gy). All treatments were delivered in 25 
fractions. Patients were treated according to a Phase I-II 
dose-escalation study. Toxicity was scored by CTC-AE v. 3.0 
scale.  
 
Results: Sixty-six HIR-EC patients were enrolled. The Level 1 
group included 38 patients while Level 2 group included 28 
patients. Clinico-pathological characteristics of the two 
groups are reported in Table 1. All patients completed 
radiation treatment without interruption. No differences 
were found between the 2 groups in terms of skin, 
gastrointestinal and genitourinary toxicities. 
 
 
 
With a median follow up of 20 months (range 3-48 months), 
no dose limiting toxicity was reported, therefore Level 2 was 
considered as the recommended dose. Three vaginal 
recurrences were documented at 8, 14 and 19 months after 
SIB-VMAT in Level 1 group. At two-years local control was 
90.4% (Level 1), versus 100% (Level 2), while disease free 
survival was 85.6% (Level 1) versus 93.3% (Level 2); overall 
survival was 96.2% ( Level 1) versus 100% (Level 2), 
respectively. 
 
Conclusion: To date, according with this phase I-II study 
clinical results, SIB-VMAT strategy represents the standard 
adjuvant treatment in HIR-EC at our Institution. We 
established the dose of 45Gy/1.8 Gy to pelvic nodes and 60 
Gy/2.4 Gy to the upper two thirds of vagina as the 
recommended doses for further evaluation of SIB- VMAT 
approaches in this setting. 
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Purpose or Objective: Minimisation of internal organ motion 
during pelvic radiotherapy (RT) is necessary to ensure 
accurate reproducible treatment. We analysed bladder and 
rectal filling during pelvic RT and their impact on CTV 
coverage. 
 
Material and Methods: Cone beam Computed Tomography 
scans (CBCTs) taken twice weekly during 3D conformal RT 
were retrospectively analysed for 10 cervical cancer patients. 
All patients followed the departmental guidelines; empty 
bladder then drink 4 cups of water 40 minutes before 
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scanning/RT; laxatives taken to ensure bowels opening daily, 
ideally Bristol stool chart type 5. Bladder, rectum and 
primary CTV were outlined on each CBCT by 2 independent 
clinicians. Effects of time through RT, chemotherapy 
administration, and drinking time on bladder and rectal 
volume were analysed. Volume variation impact on CTV 
coverage was also investigated using fixed effect logistic 
regression modelling. 
 
Results: 10 planning scans and 109 CBCTs were reviewed. 
Bladder volume was 45-578cc during radiotherapy and 73-
664cc at planning. Bladder volume increased (approx. 
4cc/minute) with waiting time, decreased (average 4cc/day) 
through RT and was larger (approx. 50cc average) on 
chemotherapy days. All bladder volumes that deviated 
>130cc from planning led to CTV being out of PTV. The odds 
of CTV remaining within PTV reduced by 1.9% for every cc 
deviation from planning volume, predominantly affecting 
uterus. Large planning bladder volumes (>300cc) were not 
reproducible during RT. Rectal anterior-posterior (AP) 
diameter correlates with rectal volume and displays no 
pattern through treatment. AP diameter ranged from 2.9-
5.3cc at planning and 1.6-8.7cc during RT. The odds of CTV 
remaining in PTV reduced by 5.8% with every mm deviation 
from planning rectal AP diameter, predominantly affecting 
cervix. 
 
Conclusion: Bladder volume changes during RT and with 
chemotherapy increase the risk of CTV being outside of PTV, 
especially the uterus. Rectal size changes increase the risk of 
CTV being outside of PTV, predominantly affecting the 
cervix. Increasing rectal size correlates with decreasing 
bladder volume, possibly due to dehydration. We therefore 
recommend an ideal bladder planning volume of 150-300cc, a 
shorter waiting time on chemotherapy days and adequate 
hydration throughout RT. We also recommend regular 
laxatives to ensure smaller rectal sizes through RT. Even with 
these recommendations, regular imaging is vital to monitor 
organ motion when implementing advanced RT techniques for 
gynaecological cancers. 
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Purpose or Objective: To retrospectively evaluate the 
effectiveness and toxicity of stereotactic body radiotherapy 
(SBRT) for localized nodal relapse (NR) of ovarian cancer.  
 
Material and Methods: Between August 2008 and March 2015, 
eleven patients were treated with SBRT on 16 NR of previous 
ovarian cancer. All patients at the time of ovarian cancer 
diagnosis were submitted to surgery and at least 1 line of 
chemotherapy (range, 1-3). Median age was 64 years (range, 
49-74), and primitive histology was siero-papillar and 
endometrioid carcinoma in 8 (72%) and 3 (28%) patients, 
respectively. Median interval time between first diagnosis 
and NR was 83 months (range, 22-148). NR was documented 
with PET-CT as the only site of disease. Response was 
evaluated with PERCIST criteria.  
 
Results: Median follow-up was 11 months (range, 2-47), 
median GTV 5.4 cc (range, 1.8-18.3), median PTV -obtained 
adding an isotropic margin of 5 mm to the GTV- 16.5 cc 
(range, 4,2-85.7). There were 11/16 (69%) sub-
diaphragmatic, 5/16 (31%) mediastinal NR. Fractionation 
schemes were: 5 x 8Gy in 10 (62%), 5 x 7Gy in 1 (6%), 5 x 6Gy 
in 1 (6%) and 5 x 5Gy in 5 (26%) NR. Outcome, evaluated with 
PET-CT 3 months after SBRT, showed a complete response in 
all treated NR, with a median duration of response of 17 
months (range, 2-47). Six (54%) patients had a subsequent 
“out-field” progression, 1 nodal and 4 peritoneal progression 
in sub-diaphragmatic region, 1 nodal progression in 
mediastinal region. The two cases with nodal progression 
received another SBRT, while the others chemotherapy. No 
acute or late toxicity was registered after SBRT. At the time 
of last follow-up, 9 patients were alive 6 of whom without 
evidence of disease.  
 
Conclusion: All ovarian cancer patients submitted to SBRT 
for NR had a durable complete response without toxicity. 
However, outcome seems less satisfying in patients with sub-
diaphragmatic disease because of peritoneal progression in 
absence of in-field relapse.  
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Purpose or Objective: The primary objective of this study 
was to evaluate the prognostic value of pretreatment 18-F-
FDG PET-CT in patients with locally advanced cervical 
cancer.  
 
Material and Methods: At pre-treatment staging, 92 patients 
with histological diagnosis of cervical cancer, underwent 18-
F-FDG PET-TC in addition to routine protocol including 
International Federation of Obstetrics and Gynecology (FIGO) 
staging and MRI. Patients were treated with concurrent 
chemoradiation followed by brachytherapy boost. 
 
Results: 18-F-FDG PET-CT identified the presence of para-
aortic lymph node metastases in 17 patients (18%). These 
patients were treated with extended field irradiation 
(including para-aortic nodes). The results of multivariate 
analysis showed that 18-F-FDG PET-CT positive para-aortic 
lymph nodes and advanced FIGO stage were predictive of 
worse disease-free survival (p=0.01; p=0.001, respectively), 
and high T SUV max had a negative impact on local control, 
disease-free survival and overall survival (p=0.02; p=0.01; 
p=0.01, respectively). 
Figure 1. Actuarial local control, Disease free survival and 
Overall survival for T SUVMAX 
 
 
 
Conclusion: High T SUV (max) showed a strong prognostic 
impact in these patients. Furthermore, staging 18-F-FDG PET-
